Dienogest in the treatment of endometriosis

Nicolò Bizzarri, Valentino Remorgida, Umberto Leone Roberti Maggiore, Carolina Scala, Scala C, Tafi E, Emanuela Tafi, E. Tafi, Ghirardi V, Valentina Ghirardi, Stefano Salvatore, Salvatore S, Massimo Candiani, Venturini PL, Pier Luigi Venturini, Simone Ferrero
Expert opinion on pharmacotherapy · 2014 · vol. 15(13) , pp. 1889–1902 · doi:10.1517/14656566.2014.943734 · PMID:25069386 · W2036135854
review OA: closed CC0 ⤵ 62 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review examines the clinical efficacy, safety, and tolerability of dienogest for endometriosis treatment, noting its effectiveness but also limitations like unproven contraceptive effects and higher cost.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Dienogest (DNG) is an oral progestin, derivative of 19-nortestosterone, that has recently been introduced for the treatment of endometriosis. AREAS COVERED: This review examines the clinical efficacy, safety and tolerability of DNG in the treatment of endometriosis. The material included in the current manuscript was searched and obtained via Medline, Pubmed and EMBASE, from inception until February 2014. The term 'dienogest' was associated with the following search terms: 'endometriosis', 'pharmacokinetics', 'safety' and 'efficacy'. EXPERT OPINION: Several trials demonstrated the clinical efficacy, safety and tolerability of DNG. However the use of DNG is associated with some limitations. So far, no study investigated the potential of contraceptive effect of this treatment and therefore, it should be recommended with other methods of contraception (e.g., barrier methods). A further limitation of the use of DNG as daily therapy in the long term is that the cost of the therapy is higher than other progestins available on the market and combined oral contraceptives. Therefore, future studies should be designed to compare the efficacy and safety of DNG with other progestins.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Nandrolone Progestins Administration, Oral Clinical Trials as Topic Endometriosis Female Humans Nandrolone Nandrolone Nandrolone Nandrolone Progestins Progestins Progestins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (58)

Cited by (50)

Source provenance

europepmc
last seen: 2026-09-02T07:05:44.937405+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:22.440000+00:00
unpaywall
last seen: 2026-09-01T06:29:04.589233+00:00
License: CC0 · commercial use OK